Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections. The Boston based biotechnology company aims to utilize Induced Pluripotent Stem Cell (“iPS”) derived pancreatic islets to cure insulin dependent diabetes.
Listed
World’s leading gene therapy company targeting multiple diseases with limited or no existing treatment.
It is the only company to date that can deliver drugs to pancreatic tumors using its innovative delivery device.
Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections. The Boston based biotechnology company aims to utilize Induced Pluripotent Stem Cell (“iPS”) derived pancreatic islets to cure insulin dependent diabetes.
Semma Therapeutics was founded to develop transformative therapies for patients who currently depend on insulin injections. The Boston based biotechnology company aims to utilize Induced Pluripotent Stem Cell (“iPS”) derived pancreatic islets to cure insulin dependent diabetes.